New US approvals turn up the generic heat on Aricept
This article was originally published in Scrip
Executive Summary
The US FDA has approved ANDAs from 15 firms for generic versions of Eisai's top selling product, the Alzheimer's disease therapy Aricept (donepezil), ratcheting up significantly the pressure on the blockbuster drug.